In the years leading up to its bankruptcy filing, the company also struggled with the growth of free or low-cost ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Following on from a remarkable study in mice, scientists have now confirmed that silencing a certain protein in muscle tissue ...

Shares of the company, which once boasted of media mogul Oprah Winfrey as one of its top shareholders, slumped 40% in ...

Founded in 1963 by Jean Nidetch, WeightWatchers began as a weekly weight-loss support group with just 400 attendees. It quickly grew into a global phenomenon, attracting millions of members worldwide ...

The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish ...

The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots ...

The WHO announced its plan to support GLP-1 weight-loss drugs, like Wegovy and Zepbound, to address the global obesity ...

Physicians describe common prior authorization challenges when treating patients for obesity and share strategies to overcome ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The head of Zealand Pharma has called its $5.3bn partnership with Roche to commercialise an obesity drug ...

Nutritional counseling remains a central component of obesity treatment, even in the era of highly effective weight-loss ...

GLP-1 receptor agonists remain blockbuster drugs for weight management for people with overweight or obesity. Increasingly, OB/GYNs and other specialists report observing fertility-related ...